Agenda Provectus Biopharmaceuticals, Inc.

Aandelen

PVCT

US74373P1084

Beurs gesloten - OTC Markets 21:57:37 03-05-2024 Variatie 5 dagen Verschil t.o.v. 1 jan (%)
0,193 USD +0,91% Intraday-grafiek van Provectus Biopharmaceuticals, Inc. -2,72% +101,15%

Grafiek agenda Provectus Biopharmaceuticals, Inc.

a5d2188084de69c6a7ac.87GFBd0mIj1CYte1V_3xwGcoHUv1u65PGiMA6Z7ageo.ncnJNrMQRQoyU6PHPZCigiJSJXvY0eM1UFRnm_KW5N2E5eBzuRBtew4Q7w~6b144f972ed94eda5d846a1472a4c151

Komende gebeurtenissen op Provectus Biopharmaceuticals, Inc.

15-05-2024 Society for Investigative Dermatology Meeting

Gebeurtenissen op naam

05-04-2024 American Association for Cancer Research Meeting
22-02-2024 21:00 Business Update Call
06-11-2023 Society for Melanoma Research Congress - Combination PV-10 autolytic immunotherapy
06-11-2023 Society for Melanoma Research Congress - Percutaneous autolytic immunotherapy
01-11-2023 Society for Immunotherapy of Cancer Meeting
01-12-2022 Melanoma Bridge Conference
22-06-2022 22:00 Annual Genral Meeting
17-06-2022 International Society of Ocular Oncology Congress
06-06-2022 20:15 American Society of Clinical Oncology Meeting - Abstract No 9543
08-04-2022 American Association of Cancer Research Meeting - Abstract No 2720
10-03-2022 European Neuroendocrine Tumor Society Conference - Abstract No: 3455, I25
28-10-2021 Society for Melanoma Research Meeting - Cutaneous Melanoma
28-10-2021 Society for Melanoma Research Congress - Checkpoint Blockade
16-09-2021 ESMO Congress Conference - Abstract No - 4354
23-06-2021 22:00 Annual Genral Meeting
09-11-2020 Society of Immunotherapy of Cancer Meeting - Abstract Number : 585
19-09-2020 European Society for Medical Oncology Virtual Congress - Poster No -4397
19-09-2020 European Society for Medical Oncology Virtual Congress - Poster No -4281
22-06-2020 American Association for Cancer Research Virtual Meeting - Abstract number: 5393
29-05-2020 American Society of Clinical Oncology Virtual Algemene vergadering - Abstract No - 1
  1. Beurs
  2. Aandelen
  3. Koers PVCT
  4. Agenda Provectus Biopharmaceuticals, Inc.